Please login to the form below

Not currently logged in
Email:
Password:

New PhRMA CEO

Business lobbyist, John J Castellani, will replace Billy Tauzin as CEO of Pharmaceutical Research and Manufacturers of America

John J Castellani, a high-profile business lobbyist, will take the top position at Pharmaceutical Research and Manufacturers of America (PhRMA), replacing Billy Tauzin, the former US Congressman who served as the trade group's president and CEO from January 2005 until earlier this year.

Castellani was most recently president and CEO of Business Roundtable, an association of chief executive officers of leading US companies – including pharma firms like Pfizer, Merck and sanofi-aventis (S-A) – which between them have almost $6trn in annual revenues and employ more than 12 million people.

Earlier in his career, Castellani served as executive vice president at the conglomerate Tenneco; vice president for resources and technology at the National Association of Manufacturers, a multi-industry trade association; and vice president of State, Federal and International Government Relations for the automotive and aerospace corporation TRW.

Castellani was selected for the role at PhRMA by a search committee led by David Brennan, president and CEO of AstraZeneca (AZ). His new position is effective September 1, 2010.

Tauzin transitioned to a position as senior advisor at PhRMA earlier this year after a leadership tenure that was generally considered successful but was marked by controversy from the beginning. Many watchdog groups and media outlets objected to his jump from chairing the House Energy and Commerce Committee, which oversees the drug industry, to the lucrative post at the top of the industry trade group.

During his time at PhRMA, Tauzin also drew fire for his role in the 2009 healthcare reform negotiations, which resulted in the industry offering the government $80bn in savings related to drug costs in return for a number of legislative concessions.

14th July 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Creative Engagement Group

We create experiences that inspire lasting change. Exceptional experiences that engage people, change mindsets and behaviour, enrich cultures, increase skills...

Latest intelligence

Lifting the fog to help Clinical Labs navigate IVDR 2022
In Vitro Diagnostic Regulation (IVDR 2022) was on the horizon: a new regulatory basis for laboratories to adhere to regarding their diagnostic equipment and tests. BD wanted to let their...
Empowering adolescents to manage emotional and mental health issues
1 in 10 UK children suffer with a mental health issue and alarmingly as many as 70% of these don’t receive the proper support they need. That’s why The Anna...
Reframing rare to increase earlier diagnosis of Gaucher Disease
Sanofi Genzyme wanted to reach haematologists; the specialist physicians most likely to encounter patients with Gaucher Disease prior to diagnosis. The problem? Gaucher Disease is considered very rare and its...